Peptide vaccines for cancers expressing tumor-associated antigens
First Claim
1. A method of treating a cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of the following (i) and (ii), or a polynucleotide encoding said peptide:
- (i) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO;
288; and
(ii) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO;
288 in which 1 or 2 amino acids are substituted.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
-
Citations
4 Claims
-
1. A method of treating a cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of the following (i) and (ii), or a polynucleotide encoding said peptide:
-
(i) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO;
288; and(ii) an isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO;
288 in which 1 or 2 amino acids are substituted. - View Dependent Claims (2, 3)
-
-
4. A method of treating cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of following (i) and (ii) or a polynucleotide encoding said peptide:
-
(i) an isolated peptide consisting of the amino acid sequence of SEQ ID NO;
288; and(ii) an isolated peptide having cytotoxic T cell inducibility, wherein said peptide consists of an amino acid sequence of SEQ ID NO;
288 in which 1 or 2 amino acids are substituted.
-
Specification